{"id":"NCT01519791","sponsor":"UCB Pharma SA","briefTitle":"A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-naïve Adults With Early Active Rheumatoid Arthritis","officialTitle":"A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate for Inducing and Sustaining Clinical Response in the Treatment of DMARD-Naïve Adults With Early Active Rheumatoid Arthritis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-01","primaryCompletion":"2014-07","completion":"2015-09","firstPosted":"2012-01-27","resultsPosted":"2015-09-22","lastUpdate":"2018-07-31"},"enrollment":880,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Rheumatoid Arthritis"],"interventions":[{"type":"BIOLOGICAL","name":"Certolizumab Pegol","otherNames":["Cimzia","CZP"]},{"type":"OTHER","name":"Placebo","otherNames":[]},{"type":"BIOLOGICAL","name":"Methotrexate","otherNames":["MTX"]}],"arms":[{"label":"Certolizumab Pegol + Methotrexate","type":"EXPERIMENTAL"},{"label":"Placebo + Methotrexate","type":"PLACEBO_COMPARATOR"}],"summary":"This study is intended to evaluate the efficacy and safety of Certolizumab Pegol (CZP) in combination with Methotrexate (MTX) for inducing and sustaining clinical response in the treatment of Disease Modifying Antirheumatic Drug (DMARD)-naïve adults with early active Rheumatoid Arthritis.","primaryOutcome":{"measure":"Percentage of Subjects in Sustained Remission at Week 52","timeFrame":"Week 52","effectByArm":[{"arm":"Placebo + Methotrexate (Full Analysis Set)","deltaMin":15,"sd":null},{"arm":"Certolizumab Pegol + Methotrexate (Full Analysis Set)","deltaMin":28.9,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":3},"locations":{"siteCount":178,"countries":["United States","Argentina","Australia","Austria","Belgium","Canada","Colombia","Czechia","France","Germany","Hungary","Ireland","Italy","Mexico","Monaco","Netherlands","Poland","Romania","Spain","Sweden","Switzerland","United Kingdom"]},"refs":{"pmids":["27165179","28666080"],"seeAlso":["http://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm"]},"adverseEventsSummary":{"seriousAny":{"events":20,"n":217},"commonTop":["Nausea","Upper respiratory tract infection","Urinary tract infection","Nasopharyngitis","Headache"]}}